These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 15866104)

  • 1. Depression and pregnancy--may selective serotonin reuptake inhibitors be associated to behavioural teratogenicity? Comment on "The obstetrician and depression during pregnancy" by Campagne DM [Eur J Obstet Gynecol Reprod Biol 116 (2) (2004) 125-30].
    Högberg U; Wang M
    Eur J Obstet Gynecol Reprod Biol; 2005 May; 120(1):123-4. PubMed ID: 15866104
    [No Abstract]   [Full Text] [Related]  

  • 2. Suicide risk during pregnancy. Comment on "The obstetrician and depression during pregnancy" by Campagne DM [Eur J Obstet Gynecol Reprod Biol 116 (2) (2004) 125-30].
    Pompili M; Ruberto A; Girardi P; Tatarelli R
    Eur J Obstet Gynecol Reprod Biol; 2005 May; 120(1):121-3; author reply 124. PubMed ID: 15866102
    [No Abstract]   [Full Text] [Related]  

  • 3. Comment on: ‘‘Campagne DM, Fact: antidepressants and anxiolytics are not safe during pregnancy.’’ Eur J Obstet Gynecol Reprod Biol 2007 Dec;135(2):145–8.
    Einarson A; Eberhard-Gran M
    Eur J Obstet Gynecol Reprod Biol; 2013 Dec; 171(2):e2. PubMed ID: 24459708
    [No Abstract]   [Full Text] [Related]  

  • 4. Pharmacotherapy for Perinatal Depression.
    Lusskin SI; Khan SJ; Ernst C; Habib S; Fersh ME; Albertini ES
    Clin Obstet Gynecol; 2018 Sep; 61(3):544-561. PubMed ID: 29561284
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Maternal use of selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn.
    Alwan S; Bandoli G; Chambers CD
    Clin Pharmacol Ther; 2016 Jul; 100(1):34-41. PubMed ID: 27060574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Treatment of depressed pregnant women by selective serotonin reuptake inhibitors: risk for the foetus and the newborn].
    Favrelière S; Nourrisson A; Jaafari N; Pérault Pochat MC
    Encephale; 2010 Jun; 36 Suppl 2():D133-8. PubMed ID: 20513456
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A rock and a hard place: The selective serotonin reuptake inhibitor dilemmas in addressing perinatal mood and anxiety disorders.
    Stohl H; Kohm AD; Dossett E
    J Neonatal Perinatal Med; 2016; 9(1):1-5. PubMed ID: 27002264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treating depression in pregnancy.
    Robert E
    N Engl J Med; 1996 Oct; 335(14):1056-8. PubMed ID: 8793933
    [No Abstract]   [Full Text] [Related]  

  • 9. SSRIs and birth defects.
    Kelly MB; Wisner KL; Cornelius MD
    Epidemiology; 2007 May; 18(3):411-2; author reply 412-3. PubMed ID: 17435454
    [No Abstract]   [Full Text] [Related]  

  • 10. Case-control studies require appropriate population controls: an example of error in the SSRI birth defect literature.
    Bracken MB
    Eur J Epidemiol; 2015 Nov; 30(11):1217-8. PubMed ID: 26518772
    [No Abstract]   [Full Text] [Related]  

  • 11. SSRIs and birth defects.
    Burt V; Miller L; Einarson A
    Epidemiology; 2007 May; 18(3):410-1; author reply 412-3. PubMed ID: 17435452
    [No Abstract]   [Full Text] [Related]  

  • 12. Neurodevelopment of children following prenatal exposure to venlafaxine, selective serotonin reuptake inhibitors, or untreated maternal depression.
    Nulman I; Koren G; Rovet J; Barrera M; Pulver A; Streiner D; Feldman B
    Am J Psychiatry; 2012 Nov; 169(11):1165-74. PubMed ID: 23128923
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Response to: Case-control studies require appropriate population controls: an example of error in the SSRI birth defect literature.
    Dolk H; Wemakor A
    Eur J Epidemiol; 2015 Nov; 30(11):1219-21. PubMed ID: 26620807
    [No Abstract]   [Full Text] [Related]  

  • 14. In utero SSRI exposure and risk of clubfoot.
    Henriksen DP; Pottegård A; Jimenez-Solem E; Damkier P
    Epidemiology; 2015 May; 26(3):e34-5. PubMed ID: 25835138
    [No Abstract]   [Full Text] [Related]  

  • 15. Is maternal use of selective serotonin reuptake inhibitors in the third trimester of pregnancy harmful to neonates?
    Koren G; Matsui D; Einarson A; Knoppert D; Steiner M
    CMAJ; 2005 May; 172(11):1457-9. PubMed ID: 15911861
    [No Abstract]   [Full Text] [Related]  

  • 16. The authors respond.
    Yazdy MM; Mitchell AA; Louik C; Werler MM
    Epidemiology; 2015 May; 26(3):e35-6. PubMed ID: 25835139
    [No Abstract]   [Full Text] [Related]  

  • 17. Selective serotonin reuptake inhibitors and autism: additional data on the Quebec Pregnancy/Birth Cohort.
    Bérard A; Boukhris T; Sheehy O
    Am J Obstet Gynecol; 2016 Dec; 215(6):803-805. PubMed ID: 27589900
    [No Abstract]   [Full Text] [Related]  

  • 18. Selective serotonin reuptake inhibitor antidepressant use in first trimester pregnancy and risk of specific congenital anomalies: a European register-based study.
    Wemakor A; Casson K; Garne E; Bakker M; Addor MC; Arriola L; Gatt M; Khoshnood B; Klungsoyr K; Nelen V; O'Mahoney M; Pierini A; Rissmann A; Tucker D; Boyle B; de Jong-van den Berg L; Dolk H
    Eur J Epidemiol; 2015 Nov; 30(11):1187-98. PubMed ID: 26148560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Findings from selective serotonin reuptake inhibitor-exposed neonates should be interpreted with caution.
    Norton JD; Worley LL; Lowery CL
    Pediatrics; 2004 Dec; 114(6):1739-40; author reply 1740-1. PubMed ID: 15574649
    [No Abstract]   [Full Text] [Related]  

  • 20. Nutritional implications of observed neurobehavioral disturbances and reduced gestation length in infants of mothers using selective serotonin reuptake inhibitors during pregnancy.
    Vavasour E
    Pediatrics; 2004 Jul; 114(1):325. PubMed ID: 15231956
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.